MRNA · News · 20261112N
Product / Drug Pipeline Progress
Moderna, Inc. · 2026-11-12 · Importance 46 · Surprise 42
At its 2026 Analyst Day, Moderna highlighted intismeran autogene, its individualized cancer therapy developed with Merck, following positive Phase 3 results in adjuvant melanoma. The company described intismeran as a lead oncology opportunity and said it had commercial and manufacturing readiness plans for the therapy. Moderna also highlighted recent approvals for its influenza vaccines mFLUSIVA and mCOFLU. Separately, peer-reviewed real-world data compared mNEXSPIKE’s effectiveness in reducing severe COVID-19 and hospitalizations among older adults with other available options.
Key facts
- Moderna detailed plans to advance intismeran, an individualized neoantigen therapy developed with Merck & Co., Inc. source
- Moderna highlighted recent approvals for its influenza vaccines mFLUSIVA and mCOFLU. source
- Moderna reported positive Phase 3 results for intismeran autogene, its individualized cancer therapy developed with Merck. source
- Moderna highlighted intismeran as a lead oncology candidate with positive Phase III results in melanoma. source
- Moderna reported publication in a peer-reviewed journal of real-world data on its mNEXSPIKE COVID-19 vaccine in older adults. source
- A study compared mNEXSPIKE's effectiveness in reducing severe COVID-19 and hospitalizations among older adults against other available options. source